



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2020

Clinicopathologic features and pathologic diagnosis of hepatitis E

Lenggenhager, Daniela ; Weber, Achim

Abstract: Infection with the hepatitis E virus (HEV) is one of the most common causes, if not the most common, of acute hepatitis worldwide. In the last decade, we have learned that in addition to the endemically and epidemically occurring form of hepatitis E, which is predominantly transmitted by contaminated drinking water, and constitutes a significant health problem in resource-poor countries, there is a globally existing form of hepatitis E, which is a zoonosis, and as such primarily transmitted by the consumption of contaminated meat products. Although in most cases hepatitis E is subclinical or mild and self-limiting, pregnant women and patients with liver cirrhosis may have severe, occasionally even fatal disease, and immunocompromised individuals may develop chronic hepatitis E. Considering the substantial global health burden caused by HEV infection, it is surprising how limited our knowledge of hepatitis E pathology still is. In this paper, we describe localization studies on HEV infection and discuss their implications for everyday diagnostics. Furthermore, we outline and discuss the spectrum of histologic changes, which can be found in HEV infection in various clinical contexts.

DOI: <https://doi.org/10.1016/j.humpath.2019.10.003>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-178864>

Journal Article

Accepted Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Lenggenhager, Daniela; Weber, Achim (2020). Clinicopathologic features and pathologic diagnosis of hepatitis E. *Human Pathology*, 96:34-38.

DOI: <https://doi.org/10.1016/j.humpath.2019.10.003>

Clinicopathologic features and pathologic diagnosis of hepatitis E

Daniela Lenggenhager, Achim Weber



PII: S0046-8177(19)30179-0

DOI: <https://doi.org/10.1016/j.humpath.2019.10.003>

Reference: YHUPA 4933

To appear in: *Human Pathology*

Received date: 1 October 2019

Accepted date: 9 October 2019

Please cite this article as: D. Lenggenhager and A. Weber, Clinicopathologic features and pathologic diagnosis of hepatitis E, *Human Pathology*(2019), <https://doi.org/10.1016/j.humpath.2019.10.003>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clinicopathologic Features and Pathologic Diagnosis of Hepatitis E

Daniela Lenggenhager¹, Achim Weber^{1,2}

¹ Department of Pathology and Molecular Pathology, University of Zurich and University Hospital Zurich, Zurich, Switzerland

² Institute of Molecular Cancer Research (IMCR), University of Zurich, 8057 Zurich, Switzerland

Correspondence to: Achim Weber

Department of Pathology and Molecular Pathology, University of Zurich and University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland; phone: +41-44-255 2781; e-mail: achim.weber@usz.ch

Key words

hepatitis E virus (HEV); histopathology; hepatitis; human liver

Number of figures and tables

1 main figure

Abbreviations

FFPE: formalin-fixed, paraffin-embedded; gt: genotype; HEV: hepatitis E virus; IHC: immunohistochemistry; ORF= open reading frame.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Financial support statement

This work was supported by grants from the Uniscientia Stiftung and the University Hospital Zurich ("USZ Innovations-Pool") to AW.

Abstract

Infection with the hepatitis E virus (HEV) is one of the most common causes, if not the most common, of acute hepatitis worldwide. In the last decade, we have learned that in addition to the endemically and epidemically occurring form of hepatitis E, which is predominantly transmitted by contaminated drinking water, and constitutes a significant health problem in resource-poor countries, there is a globally existing form of hepatitis E, which is a zoonosis, and as such primarily transmitted by the consumption of contaminated meat products. Although in most cases hepatitis E is subclinical or mild and self-limiting, pregnant women and patients with liver cirrhosis may have severe, occasionally even fatal disease, and immunocompromised individuals may develop chronic hepatitis E. Considering the substantial global health burden caused by HEV infection, it is surprising how limited our knowledge of hepatitis E pathology still is. In this paper, we describe localization studies on HEV infection and discuss their implications for everyday diagnostics. Furthermore, we outline and discuss the spectrum of histologic changes, which can be found in HEV infection in various clinical contexts.

Mini review

Hepatitis E, caused by an infection with the hepatitis E virus (HEV), which belongs to the family Hepeviridae, is one of the most frequent, perhaps even the most frequent causes of acute hepatitis worldwide, and thus represents a major global health problem.(1, 2) The question of how pathologists come into contact with hepatitis E essentially depends on which part of the world they are practicing in.(1, 3)

HEV infection is widespread worldwide, but it manifests differently depending on the geographical region. Well documented has been a major epidemic that broke out in Delhi, India, in the mid-1950s which is now considered to be the first description of hepatitis E,(4) as well as another epidemic in Kashmir in the late 1970s.(5) In the early 1980s, a new virus was identified and cloned in connection with a major outbreak of unexplained hepatitis A virus (HAV)- and hepatitis B virus (HBV)-negative hepatitis in Afghanistan, which was subsequently referred to as hepatitis E virus (HEV).(6, 7) Later on, the above mentioned Delhi and Kashmir epidemics, respectively, could also retrospectively be classified as Hepatitis E. In countries in Asia, Africa and Central America, hepatitis E often occurs in this epidemic form. It is caused by genotypes (gt) 1 and 2, and mainly transmitted by contaminated drinking water. The clinical manifestation of HEV infection is very variable.(1) In most cases, the infection is asymptomatic, but can also be severe and even lethal.(8, 9) Pregnant women and patients with a pre-existing severe liver disease are particularly at risk of worse outcome.(5, 10)

A few years ago, our perception of hepatitis E started to change, after it had become obvious that, in addition to the epidemic form described above, there is another manifestation of hepatitis E which represents a zoonosis occurring globally including in particular also Europe and North America.(11-14) This autochthonous form of hepatitis E is caused by the worldwide occurrence of gt3, and in Asia by the additional occurrence of gt4. The main

reservoir for these viruses are pigs and wild boars.(1) The virus is transmitted mainly through the consumption of meat products that are not cooked sufficiently. What was surprising at that time was the realization that autochthonous HEV infection can also lead to chronic progressions in immunocompromised individuals,(15-18) which in this form had not been described before in the epidemic form.

At the molecular and cell biological level, we now have a solid understanding of central processes of HEV infection, in particular of the function of the three major proteins encoded by three different open reading frames (ORF). While the ORF1 protein (pORF1) is responsible for virus replication, the ORF2 protein (pORF2) is the capsid, which also forms the main antigenic structure and is used for vaccination. The ORF3 (pORF3) protein in turn is responsible for the release of viral particles from the cell.(2, 19)

Considering the frequency of hepatitis E worldwide and the large global health burden it represents, it is amazing how rudimentary the picture was until recently that we had of the course of infection in vivo, especially in the tissue context of the human liver. Insights into the life cycle of the virus could be gained in recent years by analyzing chimeric mice with human liver cells.(20-22) Although these models are suitable to study the life cycle in the 3D tissue context, and also allow to perform drug testing, they are limited in that the natural cellular and humoral human immune response cannot be recapitulated.(23, 24) Our own group has recently performed systematic analyses on the localization of HEV RNA and the three major HEV proteins (pORF1, pORF2 and pORF3) not only in the cell culture system but also in liver tissue of hepatitis E patients. Following this approach, we were able to perform in situ RNA hybridization and immunohistochemistry on formalin-fixed, paraffin-embedded (FFPE) tissue, allowing us to simultaneously localize HEV RNA and proteins directly in human livers, and semi-quantitatively describe the subcellular localization of the three proteins.(25) We made interesting observations especially for the HEV pORF2 protein. On the one hand, we were able to show that this protein is also found in the nucleus of infected hepatocytes, which

was surprising at the time, but has now been confirmed by other groups.(26) On the other hand, we were able to show that pORF2, unlike pORF1 and pORF3, can also be visualized very well in FFPE material of HEV-infected livers, so that the immunohistochemistry of pORF2 can also be used for diagnostic purposes. **(FIGURE 1 A)** This provides us a robust method for the histopathologic diagnosis of hepatitis E.(27, 28)

Immunohistochemistry for the presentation of HEV infection is a valuable ancillary test in everyday diagnostics, since the histologic changes that can occur in hepatitis E are very variable, thus making the histopathologic differential diagnosis of hepatitis E really challenging.(29) Compared to other viral hepatitis, there are few reports on histologic changes.(30) The histology of the epidemic form of hepatitis E has already been described in detail in the context of the above mentioned historical hepatitis epidemic in India in a substantial case number cohort of 90 biopsies, whereby a cholestatic form was distinguished from a non-cholestatic form.(31) In reports on the acute autochthonous form of hepatitis E with significantly smaller case numbers, changes similar to those observed in hepatitis A were described.(32-34) In summary, key histologic features of the acute hepatitis pattern are: Expanded portal tracts with a mixed infiltrate including lymphocytes, plasma cells and granulocytes, lobular disarray, Kupffer cell activation, variable degree of (mostly spotty) hepatocyte necrosis, hepatocyte swelling and ballooning degeneration, cholestatic rosettes, canalicular and cytoplasmic bilirubinostasis, biliary epithelial damage, and cholangitis.(30, 35) **(FIGURE 1 B)**

In reports on persistent / chronic courses of HEV infection in immunosuppressed patients, histologic changes similar to those in other forms of chronic hepatitis were described, including the development of portal-emphasized chronic inflammation and fibrosis.(15, 36) Furthermore, cases with almost only reactive changes(36) or a prominent cholangitic component(37) have been described. In summary, key histologic features of the chronic hepatitis pattern are: Portal-based mononuclear inflammation (predominantly lymphocytes),

interface activity possible, variable degree of hepatocyte necrosis (mostly single scattered apoptotic hepatocytes), and variable degree of fibrosis possible.(30) **(FIGURE 1 C)**

The above mentioned compilation of reports on hepatitis E-associated histopathologic changes, supplemented by our own observations,(29, 35) shows how heterogeneous the histopathologic findings in hepatitis E are. Thus, it becomes clear that these changes overlap extensively with histologic changes observed in other diseases. For the acute, self-limiting form of hepatitis E, these are mainly: Hepatotrophic viruses other than E, non-hepatotropic viruses, autoimmune hepatitis (AIH), drug-induced liver injury and toxins as well as metabolic diseases (e.g. Wilson's disease). For the chronic form of hepatitis E, these are mainly: Hepatotrophic viruses other than E, non-hepatotropic viruses, autoimmune hepatitis (AIH), drug-induced liver injury,(38) and in the context of transplantation also T-cell mediated rejection in (liver) transplant patients, graft versus host disease (GvHD) in hematologic stem cell transplanted patients, and recurrence of viral hepatitis.

In a special situation are patients with pre-existing (severe) liver disease in whom an additional hepatitis E infection is more difficult to detect clinically and histopathologically against the background of the pre-existing disease.(39-41) **(FIGURE 1 D)** It is therefore given that differential diagnosis is extremely challenging, which is made even more difficult by the fact that the clinical pictures also overlap. Therefore, the correlation with the clinical context, which is generally recommended in hepatopathology, is especially important for hepatitis E.

In summary, immunohistochemistry for HEV pORF2 has become a robust and helpful tool for histopathologic diagnostics. The fact that hepatitis E associated histologic changes cover a very broad spectrum ranging from a nearly normal liver histology, over acute and chronic hepatitis patterns to (sub)-total liver necrosis, together with the notion that no pathognomonic or even characteristic changes could be defined so far (and probably do not exist), makes the histopathologic diagnosis very challenging. Since the manifestation is different depending

on the clinical context, it is advisable to consider this for the differential diagnosis of hepatitis E in everyday life.

Acknowledgments

We would like to thank our pathology colleagues and clinicians for the fruitful collaboration and for providing precious liver biopsy material, as well as our technicians for the excellent technical support.

FIGURE LEGEND

Fig. 1. Histopathologic findings observed in liver biopsies from patients with HEV infection: (A) HEV-pORF2 immunohistochemistry with geographically distributed positive areas and different staining patterns: e.g. predominantly cytoplasmic (upper insert) or predominantly nuclear (lower insert). (B) Acute hepatitis pattern with severe lobular disarray, hepatocyte damage and cholestasis. (C) Chronic hepatitis pattern with portal-based mononuclear inflammation, some interface activity, single scattered apoptotic hepatocytes (arrow head) and development of fibrosis (insert Sirius red). (D) Acute on chronic liver damage pattern with signs of nutritive-toxic damage, inflammation and cirrhosis (insert Sirius red). Scale bars 250 μm for H&E overviews in A-D and Sirius red in C-D; scale bar 25 μm for inserts in A and B.

References

1. Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, Dalton HR. Hepatitis E virus infection. Nat Rev Dis Primers 2017; 3, 17086.
2. Nimgaonkar I, Ding Q, Schwartz RE, Ploss A. Hepatitis E virus: advances and challenges. Nat Rev Gastroenterol Hepatol 2017.

3. Dalton HR, Izopet J. Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections. Cold Spring Harbor perspectives in medicine 2018; 8.
4. Viswanathan R. Epidemiology. Indian J Med Res 1957; 45, 1-29.
5. Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980; 68, 818-824.
6. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, Bradley DW. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990; 247, 1335-1339.
7. Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, Poleschuk VF. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 1983; 20, 23-31.
8. Lau JY, Sallie R, Fang JW, Yarbough PO, Reyes GR, Portmann BC, Mieli-Vergani G, Williams R. Detection of hepatitis E virus genome and gene products in two patients with fulminant hepatitis E. J Hepatol 1995; 22, 605-610.
9. Peron JM, Bureau C, Poirson H, Mansuy JM, Alric L, Selves J, Dupuis E, Izopet J, Vinel JP. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat 2007; 14, 298-303.
10. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981; 70, 252-255.
11. Dalton HR, Webb GW, Norton BC, Woolson KL. Hepatitis E Virus: Time to Change the Textbooks. Dig Dis 2016; 34, 308-316.
12. Kupferschmidt K. Europe's new hepatitis problem. Science 2016; 353, 862-863.
13. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008; 48, 494-503.
14. Horvatits T, Ozga AK, Westholter D, Hartl J, Manthey CF, Lutgehetmann M, Rauch G, Kriston L, Lohse AW, Bendall R, Wedemeyer H, Dalton HR, Pischke S. Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. Liver Int 2018.
15. Kamar N, Selves J, Mansuy JM, Ouezani L, Peron JM, Guitard J, Cointault O, Esposito L, Abravanel F, Danjoux M, Durand D, Vinel JP, Izopet J, Rostaing L. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358, 811-817.
16. Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008; 358, 859-860.
17. Gerolami R, Moal V, Picard C, Colson P. Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. J Hepatol 2009; 50, 622-624.
18. Haagsma EB, Niesters HG, van den Berg AP, Riezebos-Brilman A, Porte RJ, Vennema H, Reimerink JH, Koopmans MP. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009; 15, 1225-1228.
19. Debing Y, Moradpour D, Neyts J, Gouttenoire J. Update on hepatitis E virology: Implications for clinical practice. J Hepatol 2016; 65, 200-212.
20. Allweiss L, Gass S, Giersch K, Groth A, Kah J, Volz T, Rapp G, Schobel A, Lohse AW, Polywka S, Pischke S, Herker E, Dandri M, Lutgehetmann M. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. J Hepatol 2016; 64, 1033-1040.
21. Sayed IM, Verhoye L, Cocquerel L, Abravanel F, Foquet L, Montpellier C, Debing Y, Farhoudi A, Wychowski C, Dubuisson J, Leroux-Roels G, Neyts J, Izopet J, Michiels T, Meuleman P. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. Gut 2017; 66, 920-929.
22. van de Garde MD, Pas SD, van der Net G, de Man RA, Osterhaus AD, Haagmans BL, Boonstra A, Vanwolleghem T. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection. J Virol 2016; 90, 4394-4401.
23. Feng Z, Lemon SM. Innate Immunity to Enteric Hepatitis Viruses. Cold Spring Harb Perspect Med 2018.
24. Walker CM. Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections. Cold Spring Harb Perspect Med 2018.
25. Lenggenhager D, Gouttenoire J, Malehmir M, Bawohl M, Honcharova-Biletska H, Kreutzer S, Semela D, Neuweiler J, Hurlimann S, Aepli P, Fraga M, Sahli R, Terracciano L, Rubbia-Brandt L, Mullhaupt B, Sempoux C, Moradpour D, Weber A. Visualization of hepatitis E virus RNA and proteins in the human liver. J Hepatol 2017; 67, 471-479.
26. Ankavay M, Montpellier C, Sayed IM, Saliou JM, Wychowski C, Saas L, Duvet S, Aliouat-Denis CM, Farhat R, de Masson d'Autume V, Meuleman P, Dubuisson J, Cocquerel L. New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle. Sci Rep 2019; 9, 6243.

27. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on hepatitis E virus infection. *J Hepatol* 2018; 68, 1256-1271.
28. Friedman LS, Lee SR, Nelson SB, Masia R. Case 36-2016. A 50-Year-Old Man with Acute Liver Injury. *N Engl J Med* 2016; 375, 2082-2092.
29. Lenggenhager D, Weber A. An Update on the Clinicopathologic Features and Pathologic Diagnosis of Hepatitis E in Liver Specimens. *Adv Anat Pathol* 2018; 25, 273-281.
30. Cullen JM, Lemon SM. Comparative Pathology of Hepatitis A Virus and Hepatitis E Virus Infection. *Cold Spring Harb Perspect Med* 2018.
31. Gupta DN, Smetana HF. The histopathology of viral hepatitis as seen in the Delhi epidemic (1955-56). *Indian J Med Res* 1957; 45, 101-113.
32. Peron JM, Danjoux M, Kamar N, Missouri R, Poirson H, Vinel JP, Mansuy JM, Bureau C, Izopet J, Brousset P, Selves J. Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. *Virchows Arch* 2007; 450, 405-410.
33. Malcolm P, Dalton H, Hussaini HS, Mathew J. The histology of acute autochthonous hepatitis E virus infection. *Histopathology* 2007; 51, 190-194.
34. Drebber U, Odenthal M, Aberle SW, Winkel N, Wedemeyer I, Hemberger J, Holzmann H, Dienes HP. Hepatitis E in liver biopsies from patients with acute hepatitis of clinically unexplained origin. *Front Physiol* 2013; 4, 351.
35. Lenggenhager D, Weber A. Hepatitis E Virus and the Liver: Clinical Settings and Liver Pathology. *Gastroenterol Clin North Am* 2017; 46, 393-407.
36. Protzer U, Bohm F, Longerich T, Seebach J, Heidary Navid M, Friemel J, Marques-Maggio E, Bawohl M, Heikenwalder M, Schirmacher P, Dutkowski P, Clavien PA, Schemmer P, Schnitzler P, Gotthardt D, Mullhaupt B, Weber A. Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. *Mod Pathol* 2015; 28, 523-532.
37. Beer A, Holzmann H, Pischke S, Behrendt P, Wrba F, Schlue J, Drebber U, Neudert B, Halilbasic E, Kreipe H, Lohse A, Sterneck M, Wedemeyer H, Manns M, Dienes HP. Chronic Hepatitis E is associated with Cholangitis. *Liver Int* 2019.
38. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, Nguyen H, Emerson SU, Purcell RH, Tillmann HL, Gu J, Serrano J, Hoofnagle JH, Drug-Induced Liver Injury N. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. *Gastroenterology* 2011; 141, 1665-1672 e1661-1669.
39. Dalton HR. Hepatitis: hepatitis E and decompensated chronic liver disease. *Nat Rev Gastroenterol Hepatol* 2012; 9, 430-432.
40. Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, Siddiqui A, Jafri W. Hepatitis E virus superinfection in patients with chronic liver disease. *Hepatology* 2002; 36, 474-478.
41. Kumar Acharya S, Kumar Sharma P, Singh R, Kumar Mohanty S, Madan K, Kumar Jha J, Kumar Panda S. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. *J Hepatol* 2007; 46, 387-394.




Figure 1